PCSA_OUT_1 [2025-04-02 07:55:05 -0400] 3220 Bytes | 805 tokens | Cum: 805 tkns (10.06% of 8k)
==========================================================================

You're the expert here today. So, I pulled together a bunch of data for you to look over real fast. I'm looking at high-performance stocks today and Processa Pharmaceuticals (PCSA) hit my radar screen, up to 0.5414 from a prev close of 0.412 Do you think its got more juice or is it lacking potential? It's 7:55:04 AM on Wed Apr 02, 2025 -0400 and I have to decide: buy or sell!

--- COMPANY PROFILE ---
Company: Processa Pharmaceuticals (PCSA)
IPO: 2013-10-07 (11 Years Ago)
Market Cap: $2,170,927
Shares Outstanding: 5,270,000
Industry: PHARMACEUTICAL PREPARATIONS
Exchange: XNAS
Description: Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).

Here's the first list of news for Processa Pharmaceuticals:

C1 - Mar-18-25 08:30AM - Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference
C2 - Feb-21-25 03:48AM - Processa Pharmaceuticals, Inc. (PCSA): Among the Cheapest Stocks Insiders Are Buying Recently
C3 - Feb-07-25 08:00AM - Processa Pharmaceuticals to Present at the 2025 BIO CEO & Investor Conference
C4 - Jan-30-25 05:17PM - Processa Pharmaceuticals Announces Closing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules
C5 - Jan-27-25 08:30PM - Processa Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules
C6 - Oct-30-24 04:15PM - Processa Pharmaceuticals Reports Third Quarter Business Highlights and Financial Results
C7 - Oct-02-24 04:05PM - Processa Pharmaceuticals Announces First Patient Dosed in Phase 2 Clinical Trial of NGC-Cap in Metastatic Breast Cancer
C8 - Sep-03-24 08:00AM - Processa Pharmaceuticals to Participate in Investor and Industry Conferences During September

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on Processa Pharmaceuticals (PCSA)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

PCSA_OUT_3 [2025-04-02 07:55:09 -0400] 1100 Bytes | 264 tokens | Cum: 1071 tkns (13.39% of 8k)
==========================================================================

Showing C2 (chunk 1 of 6): C2:
**Processa Pharmaceuticals, Inc. (PCSA): Among the Cheapest Stocks Insiders Are Buying Recently**
Date: Feb-21-25 03:48AM
Source: (Insider Monkey)
URL: https://finance.yahoo.com/news/processa-pharmaceuticals-inc-pcsa-among-084825420.html

We recently published a list of10 Cheapest Stocks Insiders Are Buying Recently. In this article, we are going to take a look at where Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) stands against the other cheap stocks insiders are buying recently.

Why should we be interested in affordable stocks? Some investors like to look for cheaper stocks in order to diversify their portfolios, because these penny stocks often operate in different industries than larger businesses.

Some investors’ strategy is finding nascent companies with strong growth potential, which can bring high returns once the companies have grown. Even though penny stocks often carry h

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

PCSA_OUT_5 [2025-04-02 07:55:11 -0400] 757 Bytes | 190 tokens | Cum: 1333 tkns (16.66% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-03-18T12:51:24Z - Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference...
A2 - 2025-03-18T12:46:15Z - Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference | Taiwan...
A3 - 2025-03-18T12:38:59Z - Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

PCSA_OUT_7 [2025-04-02 07:55:14 -0400] 1098 Bytes | 302 tokens | Cum: 1637 tkns (20.46% of 8k)
==========================================================================

Showing A1 (chunk 1 of 3): A1:
**Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference**Date: 2025-03-18Source: {'uri': 'manilatimes.net', 'dataType': 'news', 'title': 'The Manila times'}URL: https://www.manilatimes.net/2025/03/18/tmt-newswire/globenewswire/processa-pharmaceuticals-to-present-at-the-medinvest-biotech-and-pharma-investor-conference/2075303Prenetics' IM8 Health Expands Scientific Advisory Board, Reinforcing Commitment to Set New Standards in Supplements Market

HANOVER, Md., March 18, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next generation cancer therapies with improved efficacy and safety, today announced its participation in the MedInvest Biotech and Pharma Investor Conference being held March 27-28, 2025, at Cooley's law office in New Yo

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

PCSA_OUT_9 [2025-04-02 07:55:14 -0400] 1077 Bytes | 304 tokens | Cum: 2002 tkns (25.02% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2025-02-07T13:00:00Z - Processa Pharmaceuticals to Present at the 2025 BIO CEO & Investor Conference
B2 - 2025-01-30T22:17:00Z - Processa Pharmaceuticals Announces Closing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules
B3 - 2025-01-28T01:30:00Z - Processa Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules
B4 - 2024-09-03T12:00:00Z - Processa Pharmaceuticals to Participate in Investor and Industry Conferences During September
B5 - 2024-06-11T12:20:00Z - Processa Pharmaceuticals Announces Positive Efficacy Results from Preliminary Evaluation of Phase 1b Dose-escalating Trial with NGC-Cap in Gastrointestinal Cancer
B6 - 2024-05-06T12:00:00Z - Processa Pharmaceuticals to Participate in the EF Hutton Annual Global Conference

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

PCSA_OUT_11 [2025-04-02 07:55:17 -0400] 778 Bytes | 209 tokens | Cum: 2213 tkns (27.66% of 8k)
==========================================================================

Showing B2 (chunk 1 of 1): B2:
**Processa Pharmaceuticals Announces Closing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2025/01/30/3018488/0/en/Processa-Pharmaceuticals-Announces-Closing-of-5-Million-Public-Offering-Priced-At-The-Market-Under-Nasdaq-Rules.htmlProcessa Pharmaceuticals, a clinical-stage pharmaceutical company, announced the closing of a $5 million public offering. The offering included the sale of common stock and warrants to institutional investors and company insiders.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

PCSA_OUT_13 [2025-04-02 07:55:17 -0400] 1119 Bytes | 267 tokens | Cum: 2529 tkns (31.61% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-03-20 10-K Item 7. Mgts Discussion and Analysis of the Results of Oper

You should read the following discussion and analysis of our financial condition and results of operations together with our CONS financial statements and the related notes and other financial inf...

S2 - 2025-02-11 8-K Item 7.01. Regulation Disclosure.

A copy of a slide presentation (Presentation Materials) that Processa Pharmaceuticals, Inc. (Processa Pharmaceuticals) intends to publish to its website, is attached to this Curr Report on Form 8-K and Exhibit 99.1. The Presentation Material...

S4 - 2025-01-30 8-K Item 1.01 Entry into a Material Definitive Agrmt.

On January 27, 2025, Processa Pharmaceuticals, Inc. (the Company) entered into a securities purchase agreement (the Securities Purchase Agrmt) with a healthcare focused institutional investor pursuant to which the Compan...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

PCSA_OUT_15 [2025-04-02 07:55:18 -0400] 1098 Bytes | 233 tokens | Cum: 2764 tkns (34.55% of 8k)
==========================================================================

Showing S1 (chunk 1 of 6): S1:
Item 7. Managements Discussion and Analysis of the Results of Operations

You should read the following discussion and analysis of our financial condition and results of operations together with our consolidated financial statements and the related notes and other financial information included elsewhere in this Annual Report on Form 10-K. Some of the information contained in this discussion and analysis contains forward-looking statements that involve risks and uncertainties. You should review the section titled Risk Factors in this Annual Report on Form 10-K for a discussion of important factors that could cause actual results to differ materially from the results described below.

Overview

We are a clinical-stage biopharmaceutical company developing a pipeline of Next Generation Cancer therapy (NGC) small molecules, two of which are in, or have completed, Phase 2 trials, and o

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

PCSA_OUT_17 [2025-04-02 07:55:19 -0400] 1098 Bytes | 227 tokens | Cum: 2993 tkns (37.41% of 8k)
==========================================================================

Showing S1 (chunk 2 of 6): ne is in pre-clinical development. Our risk-mitigated strategy is to identify existing cancer therapies where the mechanism of action is well understood and that are cornerstones of current treatment regimens, but are highly toxic, with side effects that are often treatment limiting (see Our Strategy above). We devise technologies to change the way the body metabolizes them, or the way they are distributed within the body, to improve the therapeutic effect and reduce toxicity. We then efficiently develop our pipeline of Next Generation Cancer therapies utilizing our proprietary Regulatory Science Approach (see Regulatory Science Approach above), which we believe will further increase the likelihood of regulatory approval. Since the underlying drugs are already commonly used in cancer therapy, we believe that if our clinical trials are successful and are showing better efficacy and tolera

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

PCSA_OUT_19 [2025-04-02 07:55:29 -0400] 4673 Bytes | 1364 tokens | Cum: 4359 tkns (54.49% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+---------------------+-----------------------+-----------------------+---------------------+
| Volume: 909,564 | Perf Month: -16.09% | Option/Short: No / No | Sales Y/Y TTM: - |
+---------------------+-----------------------+-----------------------+---------------------+
| Avg Volume: 235.72K | Perf Quarter: -54.73% | Short Float: 2.08% | ROE: -354.51% |
+---------------------+-----------------------+-----------------------+---------------------+
| Rel Volume: 3.88 | Index: - | Short Ratio: 0.40 | ROI: -698.44% |
+---------------------+-----------------------+-----------------------+---------------------+
| RSI (14): 36.87 | Market Cap: 2.17M | Short Interest: 0.10M | Sales Surprise: - |
+---------------------+-----------------------+-----------------------+---------------------+
| ATR (14): 0.05 | Shs Outstand: 5.27M | Beta: 1.31 | EPS Surprise: 8.88% |
+---------------------+-----------------------+-----------------------+---------------------+
| SMA20: -5.56% | Shs Float: 4.59M | Sales Q/Q: - | P/E: - |
+---------------------+-----------------------+-----------------------+---------------------+
| SMA50: -23.36% | Inst Own: 1.88% | Sales past 5Y: 0.00% | Earnings: Mar 27 |
+---------------------+-----------------------+-----------------------+---------------------+
| SMA200: -64.22% | Insider Own: 12.83% | Employees: 10 | |
+---------------------+-----------------------+-----------------------+---------------------+
| Perf Week: 3.00% | Insider Trans: 65.50% | Debt/Eq: 0.04 | |
+---------------------+-----------------------+-----------------------+---------------------+

The next section covers any insider trading.
If this section may be blank due to no recent filings.

Inside Trans: Processa Pharmaceuticals, Inc. (PCSA) by Yorke Justin W (Unknown Title) on 2025-01-27
- Common Stock: 12400 shares at $0.7975 (I)

Inside Trans: Processa Pharmaceuticals, Inc. (PCSA) by Lin Patrick (Chief Business - Strategy Off) on 2025-01-27
- Common Stock: 43500 shares at $0.7975 (I)

Inside Trans: Processa Pharmaceuticals, Inc. (PCSA) by Young David (Pres. Research & Development) on 2025-01-27
- Common Stock: 124500 shares at $0.7975 (D)

Inside Trans: Processa Pharmaceuticals, Inc. (PCSA) by Ng George K (Chief Executive Officer) on 2025-01-27
- Common Stock: 87200 shares at $0.7975 (I)

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): N/A
Net Income: {'value': -11850118.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 0.412
Average Volume: 123477.59
30-Day High: 0.51
30-Day Low: 0.37

[Detailed Financials: TTM 2024]
- Total Assets: $3,229,289.0
- Total Liabilities: $1,533,118.0
- Total Equity: $1,696,171.0
- Current Assets: $1,873,619.0
- Current Liabilities: $1,532,631.0

[Income Statement: TTM 2024]
- Revenue: N/A
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -3.87

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $-3,514,872.0

[Detailed Financials: FY 2024]
- Total Assets: $3,229,289.0
- Total Liabilities: $1,533,118.0
- Total Equity: $1,696,171.0
- Current Assets: $1,873,619.0
- Current Liabilities: $1,532,631.0

[Income Statement: FY 2024]
- Revenue: N/A
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -3.87

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $-3,514,872.0
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.

Now, complete this report with the following:

1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]

1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

PCSA_OUT_21 [2025-04-02 07:55:31 -0400] 676 Bytes | 167 tokens | Cum: 4799 tkns (59.99% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)

PCSA_IN_23 [2025-04-02 07:55:32 -0400] 126 Bytes | 29 tokens | Cum: 4856 tkns (60.70% of 8k)
==========================================================================

====================================
[2025-04-02 07:55:32] # Analysis Completed
Elapsed Time: 27.26 seconds